GNW: FDA accepts the new drug application for review of Idorsia's daridorexant | Newsticker
for the treatment of adult patients with insomnia • The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime functioning, while maintaining a favorable safety profile Allschwil, Switzerland - March 10, 2021 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has accepted the new drug application (NDA) for review of Idorsia's investigational dual orexin receptor antagonist, daridorexant, for the treatment of ad...